# Grow each trial patient's tumour as organoids to decide which platform arm opens next

Source: https://onco.cc/ideas/idea-tr2-organoid-coclinical-arms/  
OnCo record `idea-tr2-organoid-coclinical-arms` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

While patients are treated in a platform trial, their tumour cells grow in a dish and are tested against dozens of drug pairs. The pairs that win in the dish become the next arms.

## Summary

Co-clinical organoid programmes (for example in pancreatic and colorectal cancer) have tested whether dish responses predict patient responses. The proposal inverts the use: a platform trial's organoid bank becomes a combination discovery engine, testing hundreds of pairs on the same tumours that are being treated, so the next arm is chosen from data on the trial population itself rather than on generic cell lines.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Arms nominated by co-clinical organoid screening achieve a higher objective response rate than arms nominated by investigator choice in the same platform, with the difference visible after two rounds of arm selection.
- Rationale: Organoid sensitivity correlates with patient response for cytotoxics and some targeted agents. Pairs tested on the actual trial population avoid the mismatch between cell-line panels and the patients enrolled.
- Proposed test: Add a co-clinical organoid screen to an existing pancreatic or colorectal platform; nominate two arms by organoid data and two by steering committee; compare response rates after 40 patients per arm.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017): https://doi.org/10.1016/j.cell.2017.11.009

## Connected records

- technologies: [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/), [Patient-derived organoids](https://onco.cc/technologies/organoids/), [PDAC organoid pharmacotyping](https://onco.cc/technologies/pdac-organoid-pharmacotyping/)
- companies: [Curesponse](https://onco.cc/companies/curesponse/), [SEngine Precision Medicine](https://onco.cc/companies/sengine/), [Xilis](https://onco.cc/companies/xilis/)
- ideas: [Patient-derived organoids to pick ADC payloads](https://onco.cc/ideas/idea-organoid-guided-adc/)
- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- bottlenecks: [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [Too many combinations to test](https://onco.cc/bottlenecks/b-combination-space/)
- key papers: [Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy](https://onco.cc/key-papers/paper-palmer-cell/)
- roadmaps: [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-tr2-organoid-coclinical-arms.json